Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials.
Loading...
Embargo End Date
ICR Authors
Authors
Liu, DHW
Šefčovičová, N
Emmerson, J
Spaans, LN
Saito, Y
Hutchins, G
Nankivell, MG
Langley, RE
Allum, W
Cunningham, D
Langer, R
Grabsch, HI
Šefčovičová, N
Emmerson, J
Spaans, LN
Saito, Y
Hutchins, G
Nankivell, MG
Langley, RE
Allum, W
Cunningham, D
Langer, R
Grabsch, HI
Document Type
Journal Article
Date
2022-07-01
Date Accepted
2022-04-16
Abstract
BACKGROUND: Adenocarcinoma with more than 50% extracellular mucin is a relatively rare histological subtype of gastrointestinal adenocarcinomas. The clinical impact of extracellular mucin in oesophageal adenocarcinoma (OeAC) has not been investigated in detail. We hypothesised that patients with mucinous OeAC (OeACmucin) do not benefit from neoadjuvant chemotherapy. METHODS: OeAC patients either treated by surgery alone in the OE02 trial (S-patients) or by neoadjuvant chemotherapy followed by surgery (CS-patients) in OE02 or OE05 trials were included. Cancers from 1055 resection specimens (OE02 [test cohort]: 187 CS, 185 S; OE05 [validation cohort]: 683 CS) were classified as either mucinous (more than 50% of the tumour area consists of extracellular mucin, OeACmucin) or non-mucinous adenocarcinoma (OeACnon-mucin). The relationship between histological phenotype, clinicopathological characteristics, survival and treatment was analysed. RESULTS: Overall, 7.3% and 9.6% OeAC were classified as OeACmucin in OE02 and OE05, respectively. In OE02, the frequency of OeACmucin was similar in S and CS-patients. Patients with OeACmucin treated with surgery alone had a poorer overall survival compared with OeACnon-mucin patients (hazard ratio: 2.222, 95% confidence interval: 1.08-4.56, P = 0.025). Patients with OeACmucin treated with neoadjuvant chemotherapy and surgery had similar survival as OeACnon-mucin patients in test and validation cohort. CONCLUSIONS: This is the first study to suggest in a post-hoc analysis of material from two independent phase III clinical trials that the poor survival of patients with mucinous OeAC can be improved by neoadjuvant chemotherapy. Future studies are warranted to identify potential underlying biological, biochemical or pharmacokinetic interactions between extracellular mucin and chemotherapy.
Citation
European Journal of Cancer, 2022, 170 pp. 140 - 148
Source Title
European Journal of Cancer
Publisher
ELSEVIER SCI LTD
ISSN
0959-8049
eISSN
1879-0852
1879-0852
1879-0852
Collections
Research Team
Medicine (RMH)